is ghk cu copper peptide Neurogan GHK-Cu Hair & Scalp Serum – 2400mg, 4% Copper Peptides – Fast-Absorbing, Water-Based Formula for Hair Softness & Shine Cu Neck GHK-CU Copper Peptide, Hair &

Rather than acting directly on hair follicles, they improve overall scalp and hair health by: Strengthening Hair: Collagen provides essential amino acids that support keratin production, the protein that forms hair strands

Split the load and you can often sit each compound at a comfortable middle amount while the combined effect still lands higher than either could alone

TB-500: Best for deep tissue and chronic injuries Why it's excellent for specific injuries: Penetrates deeper into tissues than BPC-157 Superior for muscle belly tears Improves flexibility and range of motion Reduces scar tissue formation Anti-inflammatory effects Best for: Deep muscle injuries Chronic tendon issues Limited range of motion Old injuries with scar tissue Full-body recovery Dosing: Loading: 5-10mg per week for 4-6 weeks Maintenance: 2-5mg per week Injectable subcutaneous 8-16 week protocols BPC-157 vs TB-500: BPC-157: Better for acute injuries, gut, faster results TB-500: Better for chronic issues, flexibility, deep tissue Often used together for comprehensive healing See our TB-500 guide , BPC-157 vs TB-500 comparison , and TB-500 dosage calculator

Now, convert the above to allD, threeletter notation (what your COA uses): HDLeuDThrDLeuDArgDLysDGluDProDAlaDSerDGluDIleDAlaDGlnDSerDIleDLeuDGluDAlaDTyrDSerDGlnDAsnGlyDTrpDAlaDAsnDArgDArgDSerGlyGlyDLysDArgDProDProDProDArgDArgDArgDGlnDArgDArgDLysDLysDArgGlyOH This is the 46residue Dretroinverso FOXO4derived peptide used throughout the invitro and invivo experiments in the paper and it is an exact match for the COA you uploaded

(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement